The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 22, 2023

Filed:

Dec. 17, 2019
Applicant:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Inventors:

Charleen Hunt, Dumont, NJ (US);

Jason Mastaitis, Yorktown Heights, NY (US);

Guochun Gong, Pleasantville, NY (US);

Ka-Man Venus Lai, Seattle, WA (US);

Jesper Gromada, Concord, MA (US);

Aris N. Economides, Tarrytown, NY (US);

Assignee:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01K 67/027 (2006.01); A61K 49/00 (2006.01); C07K 14/78 (2006.01);
U.S. Cl.
CPC ...
A01K 67/0275 (2013.01); A61K 49/0008 (2013.01); C07K 14/78 (2013.01); A01K 2217/00 (2013.01); A01K 2217/056 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0306 (2013.01);
Abstract

Provided are non-human animals comprising a mutation in the Fbn1 gene to model neonatal progeroid syndrome with congenital lipodystrophy (NPSCL). Also provided are methods of making such non-human animal models. The non-human animal models can be used for screening compounds for activity in inhibiting or reducing NPSCL or ameliorating NPSCL-like symptoms or screening compounds for activity potentially harmful in promoting or exacerbating NPSCL as well as to provide insights in to the mechanism of NPSCL and potentially new therapeutic and diagnostic targets.


Find Patent Forward Citations

Loading…